Tego Science, Inc.
Develops and commercializes cell therapies for regenerative medicine.
191420 | KO
Overview
Corporate Details
- ISIN(s):
- KR7191420009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
- Website:
- http://www.tegoscience.com/
- Sector:
- Manufacturing
Description
Tego Science, Inc. is a biopharmaceutical company specializing in the development and commercialization of cell therapies for regenerative medicine. The company leverages proprietary, advanced cell culture technology for the mass production of human epithelial cells. Its portfolio of approved products includes Holoderm®, an autologous cultured epidermis for severe burns; Kaloderm®, an allogeneic cell therapy for burns and diabetic foot ulcers; and Rosmir®, an autologous fibroblast treatment for wrinkles. In addition to its therapeutic products, Tego Science provides Neoderm®, a 3D cultured skin model used as an alternative to animal testing, and offers CDMO services. The company's clinical pipeline features TPX-115, a first-in-class allogeneic fibroblast-based therapy for treating rotator cuff tears, currently in late-stage clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-19 00:00 |
[기재정정]감사보고서제출
|
Korean | 27.8 KB | ||
| 2024-03-08 00:00 |
주주총회소집결의
|
Korean | 8.5 KB | ||
| 2024-03-08 00:00 |
주주총회집중일개최사유신고
|
Korean | 4.4 KB | ||
| 2024-03-08 00:00 |
[기재정정]주주총회집중일개최사유신고
|
Korean | 7.5 KB | ||
| 2024-03-08 00:00 |
주주총회소집공고
|
Korean | 144.5 KB | ||
| 2024-01-30 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 10.8 KB | ||
| 2023-12-15 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2023-11-14 00:00 |
투자판단관련주요경영사항(임상시험결과)(로스미르(TPX-105) 국내 임상시험 제3상 결과)
|
Korean | 11.7 KB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 560.9 KB | ||
| 2023-09-01 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 15.7 KB | ||
| 2023-08-14 00:00 |
반기보고서 (2023.06)
|
Korean | 982.0 KB | ||
| 2023-07-13 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(코입술주름 개선을 위한 세포치료제 TPX-121의 국내 제1상 임상시험계획(IND) 신청)
|
Korean | 8.3 KB | ||
| 2023-05-15 00:00 |
분기보고서 (2023.03)
|
Korean | 1020.4 KB | ||
| 2023-05-09 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정)(회전근개파열 세포치료제 TPX-115 제 2b/3상 임상시험계획 승인)
|
Korean | 10.8 KB | ||
| 2023-04-28 00:00 |
투자판단관련주요경영사항(회전근개 전층 파열 세포치료제 TPX-114 국내 제1/3상 임상시험 결과)
|
Korean | 12.1 KB |
Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tego Science, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
